Skip to main content

Table 1 Baseline Characteristics

From: Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma

Characteristics TACE-alone group
(N = 51)
(No, %; Mean ± SD)
TACE-camrelizumab group (N = 20)
(No, %; Mean ± SD)
P value
Gender    0.223
 Male 43 (84.3%) 19 (95%)  
 Female 8 (15.7%) 1 (5%)  
Age (years) 52.5 ± 10.7 50.3 ± 11.3 0.045
ECOG
performance
   0.769
 0 21(41.2%) 9(45%)  
 1 30(58.8%) 11(55%)  
Hepatitis    0.428
 Hepatitis B 39 (76.5%) 17 (85%)  
 Other 12 (23.5%) 3 (15%)  
Child–Pugh class    0.101
 A 49 (96.1%) 17 (85%)  
 B 2 (3.9%) 3 (15%)  
BCLC stage    0.113
 B 14(27.5%) 2 (10%)  
 C 37(72.5%) 18 (90%)  
TB (µmol/L) 19.08 ± 6.78 20.56 ± 10.6 0.486
Albumin (g/L) 37.3 ± 5.5 35.8 ± 3.00 0.064
PT(s) 14.1 ± 1.4 13.9 ± 1.1 0.600
AST (µmol/L) 39.2 ± 44.0 55.4 ± 23.2 0.124
ALT (µmol/L) 33.8 ± 21.0 39.5 ± 17.0 0.285
PLR 142.6 ± 75.9 157 ± 83.0 0.477
NLR 3.9 ± 1.8 3.5 ± 1.1 0.381
Tumor size (cm) 3.3 ± 2.3 4.1 ± 2.6 0.99
Tumor number    0.756
  = 1 11 (21.6%) 5 (25%)  
  ≥ 2 40 (78.4%) 15(75%)  
α-Fetoprotein
level
   0.280
  > 400 ng/mL 16(31.4%) 9(45%)  
  ≤ 400 ng/ml 35(68.6%) 11(55%)  
Ascites    0.254
 Absent 44(86.3%) 15(75%)  
 Present 7(13.7%) 5(25%)  
Portal vein invasion    0.531
 Yes 14(27.5%) 7(35.0%)  
 No 37(72.5%) 13(65.0%)  
Extrahepatic metastasis    0.994
 Yes 28(54.9%) 11(55.0%)  
 No 23(45.1%) 9(45.0%)  
  1. TACE: Transcatheter arterial chemoembolization; SD: Standard deviation; ECOG: Eastern Cooperative Oncology Group; TB: Total bilirubin; PT: Prothrombin time; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; BCLC: Barcelona Clinic Liver Cancer; PLR: Platelet-to-lymphocyte ratio; NLR: Neutrophil-to-lymphocyte ratio